Effect of repeated apotransferrin administrations on serum iron parameters in patients undergoing myeloablative conditioning and allogeneic stem cell transplantation.
Myeloablative conditioning prior to allogeneic stem cell transplantation causes a rapid increase in transferrin saturation and potentially toxic non-transferrin-bound iron (NTBI) in plasma. We have studied the ability of repeatedly administered apotransferrin to maintain this iron in a transferrin-bound form. Twenty adult patients undergoing myeloablative conditioning and allogeneic stem cell transplantation were enrolled to receive apotransferrin with one of three dosage regimens. Ten consecutive patients with the same preconditioning were studied as controls. At the highest dose level, full transferrin saturation and appearance of NTBI were prevented in five of the eight patients. Serum iron increased significantly more in the patients receiving apotransferrin than in the controls and remained elevated until erythropoietic recovery. From the increment of iron saturation and the amount of endogenous and administered apotransferrin, an average 180 mumol of iron per day was bound to transferrin during the first 4 d after the start of the conditioning therapy. Thereafter, iron accumulation levelled off in most patients. The results suggested that about half of the amount of iron normally transported to erythropoiesis was initially released to plasma after induction of the erythroid arrest. Complete iron binding with apotransferrin would apparently require very high apotransferrin doses.
Parkkinen
Jaakko
J
Finnish Red Cross Blood Transfusion Service, Helsinki, Finland. jaakko.parkkinen@helsinki.fi
Sahlstedt
Leila
L
von Bonsdorff
Leni
L
Salo
Hanna
H
Ebeling
Freja
F
Ruutu
Tapani
T
D000293:Adolescent; D000328:Adult; D001059:Apoproteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004920:Erythropoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007501:Iron / Q000097:blood*; D008875:Middle Aged; D011446:Prospective Studies; D014168:Transferrin / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D019172:Transplantation Conditioning
D001059:Apoproteins; D014168:Transferrin; C028284:apotransferrin; D007501:Iron